KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Non Operating Income (2021 - 2025)

Ginkgo Bioworks Holdings' Non Operating Income history spans 5 years, with the latest figure at -$10.6 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 150.22% year-over-year to -$10.6 million; the TTM value through Dec 2025 reached $1.7 million, down 86.3%, while the annual FY2025 figure was $1.7 million, 86.3% down from the prior year.
  • Non Operating Income reached -$10.6 million in Q4 2025 per DNA's latest filing, down from $9.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $82.6 million in Q1 2022 to a low of -$75.9 million in Q3 2021.
  • Average Non Operating Income over 5 years is $3.2 million, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Non Operating Income: tumbled 552.2% in 2022, then skyrocketed 688.5% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $79.1 million in 2021, then plummeted by 45.59% to $43.0 million in 2022, then crashed by 178.52% to -$33.8 million in 2023, then soared by 87.41% to -$4.3 million in 2024, then tumbled by 150.22% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Non Operating Income are -$10.6 million (Q4 2025), $9.3 million (Q3 2025), and $5.0 million (Q2 2025).